Welcome to our dedicated page for Federated Hermes SEC filings (Ticker: FHI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Federated Hermes, Inc. filings document material events for an asset-management company with liquidity, equity, fixed-income, alternative/private markets and multi-asset businesses. Recent Form 8-K reports include earnings releases, managed-asset disclosures, dividend actions, Class B common-stock consideration, acquisition terms for Federated Hermes FCP Manager, LLC and other capital-structure information.
The filing record also covers governance and executive-officer transitions, shareholder-voting matters, material agreements and legal-risk disclosures tied to investment-management subsidiaries, including Hermes GPE LLP and infrastructure fund matters. These documents connect operating results, platform expansion, leadership structure and risk disclosures to Federated Hermes' public-company reporting.
Federated Hermes (FHI) reported that it issued an earnings press release for third quarter 2025 results. The company furnished the release as Exhibit 99.1 and identified it under Item 2.02 (Results of Operations and Financial Condition).
The filing also includes Exhibit 104, the cover page interactive data file embedded within Inline XBRL. No financial details appear in this summary; readers should refer to the attached press release for the full Q3 2025 results.
Federated Hermes, Inc. (FHI) entered a material definitive agreement to acquire an 80% interest in FCP Fund Manager, L.P., a U.S. real estate investment manager with $3.8 billion of assets under management as of June 30, 2025. The total consideration is up to $331 million, comprising $215.8 million in cash, $23.2 million in FHI Class B common stock issued at closing (subject to a two-year lock-up), and up to $92 million of contingent consideration based on financial performance over multiple periods.
The transaction is expected to close in the first half of 2026, subject to customary conditions including required consents and expiration or termination of the Hart-Scott-Rodino waiting period. FHI plans to fund the cash portion with balance sheet cash and its revolving credit facility.
At closing, FCP will convert to a Delaware LLC. FHI will initially own 80% and control a seven-member board, while the Selling Parties will own 20% and appoint three directors. FCP’s management will run day-to-day operations, with key leaders entering five-year employment agreements. The deal includes buyer-side reps-and-warranties insurance, post-closing restrictive covenants, and reciprocal call/put options after the fifth anniversary for the remaining interest.
Federated Hermes, Inc. and associated parties report ownership of 1,000,000 shares of SoundThinking, Inc. common stock, representing 7.82% of the class. The filing, a Schedule 13G (Amendment No. 6), shows Federated Hermes, Inc. as having sole voting and dispositive power over the 1,000,000 shares. The same 1,000,000-share holding is reported for the Voting Shares Irrevocable Trust, and three individuals—Thomas R. Donahue, Ann C. Donahue, and J. Christopher Donahue—are reported with shared voting and dispositive power over the same aggregate amount. The signatories certify the shares were acquired in the ordinary course of business and not to influence control of the issuer.
Federated Hermes, Inc. and associated parties report ownership of 1,000,000 shares of SoundThinking, Inc. common stock, representing 7.82% of the class. The filing, a Schedule 13G (Amendment No. 6), shows Federated Hermes, Inc. as having sole voting and dispositive power over the 1,000,000 shares. The same 1,000,000-share holding is reported for the Voting Shares Irrevocable Trust, and three individuals—Thomas R. Donahue, Ann C. Donahue, and J. Christopher Donahue—are reported with shared voting and dispositive power over the same aggregate amount. The signatories certify the shares were acquired in the ordinary course of business and not to influence control of the issuer.
Federated Hermes, Inc. and related Reporting Persons report beneficial ownership of 5,116,598 shares of Scynexis Inc. common stock, representing 11.26% of the outstanding shares as of the event date 09/30/2025. The filing is an Amendment to Schedule 13G and lists ownership held by Federated Hermes, Inc., Voting Shares Irrevocable Trust, and three individual reporting persons who share voting and dispositive power over the same block. The filing states the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control. Signatures for the filing and trust acknowledgments are dated 10/07/2025, with exhibits noted for subsidiary classification, a joint filing agreement, and a power of attorney.
Federated Hermes, Inc. and related Reporting Persons report beneficial ownership of 5,116,598 shares of Scynexis Inc. common stock, representing 11.26% of the outstanding shares as of the event date 09/30/2025. The filing is an Amendment to Schedule 13G and lists ownership held by Federated Hermes, Inc., Voting Shares Irrevocable Trust, and three individual reporting persons who share voting and dispositive power over the same block. The filing states the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control. Signatures for the filing and trust acknowledgments are dated 10/07/2025, with exhibits noted for subsidiary classification, a joint filing agreement, and a power of attorney.
Federated Hermes, Inc. and affiliated reporting persons disclosed beneficial ownership of 1,635,380 shares of Forte Biosciences, Inc. common stock, representing 13.15% of the class as of the event date. The filing lists Federated Hermes, Inc. (a Pennsylvania entity) and the Voting Shares Irrevocable Trust as holders with sole voting and dispositive power over the 1,635,380 shares, while three individuals — Thomas R. Donahue, Ann C. Donahue, and J. Christopher Donahue — are reported with shared voting and dispositive power over the same aggregate amount.
The statement affirms the securities were acquired and are held in the ordinary course of business and were not acquired with the purpose of changing or influencing control of the issuer. The filing includes exhibits for classification of reporting persons, a joint filing agreement, and a power of attorney.
Federated Hermes, Inc. and affiliated reporting persons disclosed beneficial ownership of 1,635,380 shares of Forte Biosciences, Inc. common stock, representing 13.15% of the class as of the event date. The filing lists Federated Hermes, Inc. (a Pennsylvania entity) and the Voting Shares Irrevocable Trust as holders with sole voting and dispositive power over the 1,635,380 shares, while three individuals — Thomas R. Donahue, Ann C. Donahue, and J. Christopher Donahue — are reported with shared voting and dispositive power over the same aggregate amount.
The statement affirms the securities were acquired and are held in the ordinary course of business and were not acquired with the purpose of changing or influencing control of the issuer. The filing includes exhibits for classification of reporting persons, a joint filing agreement, and a power of attorney.
Federated Hermes, Inc. and related reporting persons disclose beneficial ownership of 10,544,437 shares of aTyr Pharma, Inc. common stock, representing 10.76% of the class. The filing states the shares are held in the ordinary course of business and were not acquired to change or influence control. Ownership is reported across Federated Hermes, a Voting Shares Irrevocable Trust, and three individual reporting persons who each disclose shared voting and dispositive power over the same aggregate stake. The filing includes exhibits for reporting-person classification, a joint-filing agreement, and a power of attorney.
Federated Hermes, Inc. and related reporting persons disclose beneficial ownership of 10,544,437 shares of aTyr Pharma, Inc. common stock, representing 10.76% of the class. The filing states the shares are held in the ordinary course of business and were not acquired to change or influence control. Ownership is reported across Federated Hermes, a Voting Shares Irrevocable Trust, and three individual reporting persons who each disclose shared voting and dispositive power over the same aggregate stake. The filing includes exhibits for reporting-person classification, a joint-filing agreement, and a power of attorney.
Thomas R. Donahue, identified as a Director and as VP, CFO & Treasurer of Federated Hermes, Inc. (FHI), reported a transaction on 08/28/2025 disposing of 25,525 Class B common shares (Transaction Code G). After the reported disposition the filing shows 574,948 Class B shares beneficially owned directly, plus multiple indirect holdings through trusts, partnerships and plans that together list specific amounts (for example, 421,690 via MaxFund Partners, L.P., 27,544 and 37,544 via related grantor trusts). The form was signed by an attorney-in-fact, John D. Martini, and references a Power of Attorney dated August 30, 2022.
Federated Hermes filed a Form 13F reporting the scope of assets it and affiliated advisers disclose managing. The filing lists 4,129 reported holdings entries with a total disclosed market value of $53,114,491,069. The report identifies seven other included managers and describes which affiliated advisers exercise investment discretion for portions of the portfolio, providing transparency into the firm’s structure and the scale of its publicly reported positions.